

Jane C Burns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/324917/publications.pdf>

Version: 2024-02-01

124
papers

12,257
citations

71061

41
h-index

27389

106
g-index

133
all docs

133
docs citations

133
times ranked

9116
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of SARS-CoV-2 and common cold coronavirus-specific T cell responses in MIS-C and Kawasaki disease children. <i>European Journal of Immunology</i> , 2022, 52, 123-137.	1.6	17
2	Global epidemiology of vasculitis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 22-34.	3.5	112
3	Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C. <i>Frontiers in Immunology</i> , 2022, 13, 841126.	2.2	18
4	Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial. <i>Journal of Pediatrics</i> , 2022, 243, 173-180.e8.	0.9	14
5	Neutralization of SARS-CoV-2 Omicron and other variants in serum from children with vaccination-induced myocarditis. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	0
6	Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells. <i>Clinical and Experimental Immunology</i> , 2022, 208, 361-371.	1.1	8
7	Long-term health outcomes in young adults after Kawasaki disease. <i>IJC Heart and Vasculature</i> , 2022, 40, 101039.	0.6	0
8	An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease. <i>Nature Communications</i> , 2022, 13, 2687.	5.8	37
9	Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. <i>Nature Communications</i> , 2022, 13, .	5.8	36
10	T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Have a Predominant CD4 ⁺ T Helper Response to SARS-CoV-2 Peptides and Numerous Virus-Specific CD4 ⁺ CD8 ⁻ Double-Negative T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7219.	1.8	10
11	Temporal Clusters of Kawasaki Disease Cases Share Distinct Phenotypes That Suggest Response to Diverse Triggers. <i>Journal of Pediatrics</i> , 2021, 229, 48-53.e1.	0.9	10
12	Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. <i>Circulation</i> , 2021, 143, 78-88.	1.6	226
13	Comparison Between Currently Recommended Long-Term Medical Management of Coronary Artery Aneurysms After Kawasaki Disease and Actual Reported Management in the Last Two Decades. <i>Pediatric Cardiology</i> , 2021, 42, 676-684.	0.6	5
14	Characterization of the T Cell Response to <i>Lactobacillus casei</i> Cell Wall Extract in Children With Kawasaki Disease and Its Potential Role in Vascular Inflammation. <i>Frontiers in Pediatrics</i> , 2021, 9, 633244.	0.9	2
15	IgG Epitopes Processed and Presented by IgG ⁺ B Cells Induce Suppression by Human Thymic-Derived Regulatory T Cells. <i>Journal of Immunology</i> , 2021, 206, 1194-1203.	0.4	3
16	Mistaken MIS-C: A Case Series of Bacterial Enteritis Mimicking MIS-C. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e159-e161.	1.1	18
17	Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease. <i>European Journal of Human Genetics</i> , 2021, 29, 1734-1744.	1.4	10
18	Kawasaki Disease Patient Stratification and Pathway Analysis Based on Host Transcriptomic and Proteomic Profiles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5655.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Hyponatremia in Patients With Multisystem Inflammatory Syndrome in Children. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e344-e346.	1.1	2
20	Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	31
21	Computational modeling of blood component transport related to coronary artery thrombosis in Kawasaki disease. <i>PLoS Computational Biology</i> , 2021, 17, e1009331.	1.5	14
22	Inflammasome Activation in Children With Kawasaki Disease and Multisystem Inflammatory Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2509-2511.	1.1	11
23	Biomarkers of inflammation and fibrosis in young adults with history of Kawasaki disease. <i>IJC Heart and Vasculature</i> , 2021, 36, 100863.	0.6	3
24	Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 852-861.	2.7	35
25	Temporal clustering of Kawasaki disease cases around the world. <i>Scientific Reports</i> , 2021, 11, 22584.	1.6	4
26	Biomarkers for the Discrimination of Acute Kawasaki Disease From Infections in Childhood. <i>Frontiers in Pediatrics</i> , 2020, 8, 355.	0.9	17
27	Revisiting Once Again Steroids for the Treatment of Acute Kawasaki Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e018300.	1.6	4
28	Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. <i>Journal of Pediatrics</i> , 2020, 222, 261-262.	0.9	83
29	Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnesses. <i>Archives of Disease in Childhood</i> , 2020, 105, 772-777.	1.0	5
30	High-Throughput Screening of Kawasaki Disease Sera for Antiviral Antibodies. <i>Journal of Infectious Diseases</i> , 2020, 222, 1853-1857.	1.9	9
31	Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 259.	3.8	1,528
32	Reply. <i>Journal of Pediatrics</i> , 2020, 224, 184-185.e1.	0.9	7
33	Management of Myocardial Infarction in Children with Giant Coronary Artery Aneurysms after Kawasaki Disease. <i>Journal of Pediatrics</i> , 2020, 221, 230-234.	0.9	14
34	Late-sequelae of Kawasaki disease characterized by optical coherence tomography. <i>Journal of Cardiovascular Medicine</i> , 2020, Publish Ahead of Print, 597-599.	0.6	1
35	Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis. <i>MBio</i> , 2019, 10, .	1.8	67
36	Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm. <i>Journal of Pediatrics</i> , 2019, 215, 107-117.e12.	0.9	24

#	ARTICLE	IF	CITATIONS
37	Hemodynamic variables in aneurysms are associated with thrombotic risk in children with Kawasaki disease. <i>International Journal of Cardiology</i> , 2019, 281, 15-21.	0.8	40
38	Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. <i>Journal of the American Heart Association</i> , 2019, 8, e011319.	1.6	66
39	Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. <i>Frontiers in Immunology</i> , 2019, 10, 185.	2.2	43
40	Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. <i>Pediatrics</i> , 2019, 143, .	1.0	57
41	The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. <i>Contemporary Clinical Trials</i> , 2019, 79, 98-103.	0.8	21
42	Bifid T waves on the ECG and genetic variation in <i>calcium channel voltage-dependent beta 2 subunit</i> gene (<i>CACNB2</i>) in acute Kawasaki disease. <i>Congenital Heart Disease</i> , 2019, 14, 213-220.	0.0	3
43	Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1593-1601.	1.6	15
44	Finding Kawasaki Disease. <i>Canadian Journal of Cardiology</i> , 2018, 34, 236-237.	0.8	0
45	Pediatric tolerogenic DCs expressing CD4 and immunoglobulin-like transcript receptor (ILT)4 secrete IL10 in response to Fc and adenosine. <i>European Journal of Immunology</i> , 2018, 48, 482-491.	1.6	15
46	History of the worldwide emergence of Kawasaki disease. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 13-15.	0.9	19
47	Clustering and climate associations of Kawasaki Disease in San Diego County suggest environmental triggers. <i>Scientific Reports</i> , 2018, 8, 16140.	1.6	29
48	Kawasaki disease: an essential comparison of coronary artery aneurysm criteria. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 840-841.	2.7	20
49	How Should We Classify Kawasaki Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 2974.	2.2	50
50	Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A 10-Year Experience. <i>Journal of Pediatrics</i> , 2018, 203, 408-415.e3.	0.9	48
51	Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease. <i>JAMA Pediatrics</i> , 2018, 172, e183310.	3.3	20
52	New insights into cardiovascular disease in patients with Kawasaki disease. <i>Current Opinion in Pediatrics</i> , 2018, 30, 623-627.	1.0	4
53	Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature. <i>JAMA Pediatrics</i> , 2018, 172, e182293.	3.3	92
54	Whole blood transcriptional profiles as a prognostic tool in complete and incomplete Kawasaki Disease. <i>PLoS ONE</i> , 2018, 13, e0197858.	1.1	39

#	ARTICLE	IF	CITATIONS
55	Computational blood flow simulations in Kawasaki disease patients: Insight into coronary artery aneurysm hemodynamics. <i>Global Cardiology Science & Practice</i> , 2018, 2017, e201729.	0.3	10
56	Frequently asked questions regarding treatment of Kawasaki disease. <i>Global Cardiology Science & Practice</i> , 2018, 2017, e201730.	0.3	3
57	Management of sequelae of Kawasaki disease in adults. <i>Global Cardiology Science & Practice</i> , 2018, 2017, e201731.	0.3	7
58	Foreword to the Special Issue. <i>Global Cardiology Science & Practice</i> , 2018, 2017, e201717.	0.3	0
59	PRINCESS: Privacy-protecting Rare disease International Network Collaboration via Encryption through Software guard extensionS. <i>Bioinformatics</i> , 2017, 33, 871-878.	1.8	75
60	Usefulness of Calcium Scoring as a Screening Examination in Patients With a History of Kawasaki Disease. <i>American Journal of Cardiology</i> , 2017, 119, 967-971.	0.7	22
61	High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. <i>Journal of Pediatrics</i> , 2017, 185, 112-116.e1.	0.9	108
62	Assessment of Coronary Artery Aneurysms Caused by Kawasaki Disease Using Transluminal Attenuation Gradient Analysis of Computerized Tomography Angiograms. <i>American Journal of Cardiology</i> , 2017, 120, 556-562.	0.7	12
63	Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. <i>Circulation</i> , 2017, 135, e927-e999.	1.6	2,406
64	miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition. <i>Circulation Research</i> , 2017, 120, 354-365.	2.0	93
65	Urotensin 2 in Kawasaki disease pathogenesis. <i>Pediatric Research</i> , 2017, 82, 1048-1055.	1.1	4
66	Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease. <i>Arthritis and Rheumatology</i> , 2017, 69, 268-276.	2.9	51
67	Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates. <i>International Journal of COPD</i> , 2017, Volume 12, 961-971.	0.9	38
68	Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. <i>PLoS ONE</i> , 2017, 12, e0170977.	1.1	14
69	Urinary Colorimetric Sensor Array and Algorithm to Distinguish Kawasaki Disease from Other Febrile Illnesses. <i>PLoS ONE</i> , 2016, 11, e0146733.	1.1	4
70	Kawasaki Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1738-1749.	1.2	417
71	Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). <i>Contemporary Clinical Trials</i> , 2016, 48, 70-75.	0.8	59
72	Letter by Daniels and Burns Regarding Article, "Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review," <i>Circulation</i> , 2016, 133, e446.	1.6	0

#	ARTICLE	IF	CITATIONS
73	The Spectrum of Cardiovascular Lesions Requiring Intervention in Adults After Kawasaki Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 687-696.	1.1	73
74	Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children. <i>BMC Pediatrics</i> , 2016, 16, 151.	0.7	25
75	Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease. <i>Journal of Immunology</i> , 2016, 197, 3481-3489.	0.4	99
76	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 835.	3.8	263
77	Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	174
78	Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease. <i>European Heart Journal</i> , 2016, 38, ehv510.	1.0	1
79	Adjunctive therapies for Kawasaki disease. <i>Journal of Infection</i> , 2016, 72, S1-S5.	1.7	33
80	A Classification Tool for Differentiation of Kawasaki Disease from Other Febrile Illnesses. <i>Journal of Pediatrics</i> , 2016, 176, 114-120.e8.	0.9	16
81	Building a Natural Language Processing Tool to Identify Patients With High Clinical Suspicion for Kawasaki Disease from Emergency Department Notes. <i>Academic Emergency Medicine</i> , 2016, 23, 628-636.	0.8	44
82	Pulmonary Artery Dilation and Right Ventricular Function in Acute Kawasaki Disease. <i>Pediatric Cardiology</i> , 2016, 37, 482-490.	0.6	6
83	Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 69-76.e2.	0.6	27
84	A Novel Truncated Form of Serum Amyloid A in Kawasaki Disease. <i>PLoS ONE</i> , 2016, 11, e0157024.	1.1	8
85	Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: a Phase I/IIa trial of atorvastatin. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 967-970.	0.5	6
86	Acute Myocardial Ischemia in Adults Secondary to Missed Kawasaki Disease in Childhood. <i>American Journal of Cardiology</i> , 2015, 115, 423-427.	0.7	47
87	Novel data-mining approach identifies biomarkers for diagnosis of Kawasaki disease. <i>Pediatric Research</i> , 2015, 78, 547-553.	1.1	24
88	Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. <i>International Journal of Cardiology</i> , 2015, 201, 429-437.	0.8	25
89	The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 819-825.	1.3	96
90	Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease. <i>Autoimmunity</i> , 2015, 48, 181-188.	1.2	23

#	ARTICLE	IF	CITATIONS
91	Cardiovascular pathology in 2 young adults with sudden, unexpected death due to coronary aneurysms from Kawasaki disease in childhood. <i>Cardiovascular Pathology</i> , 2015, 24, 310-316.	0.7	35
92	Role of TGF- β 2 Signaling in Remodeling of Noncoronary Artery Aneurysms in Kawasaki Disease. <i>Pediatric and Developmental Pathology</i> , 2015, 18, 310-317.	0.5	20
93	Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. <i>Genome Medicine</i> , 2014, 6, 541.	3.6	126
94	Specificity of regulatory T cells that modulate vascular inflammation. <i>Autoimmunity</i> , 2014, 47, 95-104.	1.2	49
95	In Vitro Validation of Patient-Specific Hemodynamic Simulations in Coronary Aneurysms Caused by Kawasaki Disease. <i>Cardiovascular Engineering and Technology</i> , 2014, 5, 189-201.	0.7	28
96	Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 7952-7957.	3.3	171
97	Thrombotic risk stratification using computational modeling in patients with coronary artery aneurysms following Kawasaki disease. <i>Biomechanics and Modeling in Mechanobiology</i> , 2014, 13, 1261-1276.	1.4	53
98	Lipoprotein Particle Concentrations in Children and Adults following Kawasaki Disease. <i>Journal of Pediatrics</i> , 2014, 165, 727-731.	0.9	16
99	Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 1731-1738.	6.3	238
100	Assessing Vascular Health After Kawasaki Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1122-1123.	1.2	7
101	Kawasaki disease and ENSO-driven wind circulation. <i>Geophysical Research Letters</i> , 2013, 40, 2284-2289.	1.5	19
102	Seasonality of Kawasaki Disease: A Global Perspective. <i>PLoS ONE</i> , 2013, 8, e74529.	1.1	149
103	Image-based modeling of hemodynamics in coronary artery aneurysms caused by Kawasaki disease. <i>Biomechanics and Modeling in Mechanobiology</i> , 2012, 11, 915-932.	1.4	83
104	Finding Kawasaki disease. <i>Annals of Pediatric Cardiology</i> , 2012, 5, 133-4.	0.2	1
105	Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. <i>Human Immunology</i> , 2010, 71, 865-873.	1.2	75
106	Recognition of a Kawasaki Disease Shock Syndrome. <i>Pediatrics</i> , 2009, 123, e783-e789.	1.0	329
107	Kawasaki Disease update. <i>Indian Journal of Pediatrics</i> , 2009, 76, 71-76.	0.3	52
108	When Children With Kawasaki Disease Grow Up. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1911-1920.	1.2	223

#	ARTICLE	IF	CITATIONS
109	Resistance to Intravenous Immunoglobulin in Children with Kawasaki Disease. <i>Journal of Pediatrics</i> , 2008, 153, 117-121.e3.	0.9	339
110	State-of-the-art basic and clinical science of Kawasaki disease. <i>Pediatric Health</i> , 2008, 2, 405-409.	0.3	14
111	The Riddle of Kawasaki Disease. <i>New England Journal of Medicine</i> , 2007, 356, 659-661.	13.9	65
112	Revisiting steroids in the primary treatment of acute Kawasaki disease. <i>Journal of Pediatrics</i> , 2006, 149, 291-292.	0.9	7
113	Genetic Variations in the Receptor-Ligand Pair CCR5 and CCL3L1 Are Important Determinants of Susceptibility to Kawasaki Disease. <i>Journal of Infectious Diseases</i> , 2005, 192, 344-349.	1.9	96
114	Seasonality and Temporal Clustering of Kawasaki Syndrome. <i>Epidemiology</i> , 2005, 16, 220-225.	1.2	158
115	Infliximab treatment for refractory Kawasaki syndrome. <i>Journal of Pediatrics</i> , 2005, 146, 662-667.	0.9	251
116	Kawasaki syndrome. <i>Lancet</i> , The, 2004, 364, 533-544.	6.3	849
117	Pharmacokinetic and Tolerability Assessment of a Pediatric Oral Formulation of Pentoxifylline in Kawasaki Disease. <i>Current Therapeutic Research</i> , 2003, 64, 96-115.	0.5	15
118	Kawasaki Disease: Do We Need a New Case Definition?. <i>Pediatric Research</i> , 2003, 53, 163-163.	1.1	1
119	Commentary: Translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 993-995.	1.1	81
120	Hemolymph analysis and evaluation of newly formulated media for culture of shrimp cells (<i>Penaeus</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	27
121	INFECTION OF CULTURED EMBRYO CELLS OF THE PACIFIC OYSTER, <i>CRASSOSTREA GIGAS</i> , BY PANTROPIC RETROVIRAL VECTORS. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2000, 36, 395.	0.7	23
122	Summary and Abstracts of the Sixth International Kawasaki Disease Symposium. <i>Pediatric Research</i> , 2000, 47, 544-570.	1.1	9
123	The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin. <i>New England Journal of Medicine</i> , 1986, 315, 341-347.	13.9	1,352
124	RNA Sequencing Reveals Beneficial Effects of Atorvastatin on Endothelial Cells in Acute Kawasaki Disease. <i>Journal of the American Heart Association</i> , 0, , .	1.6	2